NasdaqCM:OTLKBiotechs
Outlook Therapeutics (OTLK) Stock After FDA Class 1 BLA Resubmission Is The Valuation Out Of Line
Outlook Therapeutics (OTLK) has moved back into focus after resubmitting its Biologics License Application to the FDA for ONS-5010/LYTENAVA for wet age related macular degeneration, following a successful appeal of a prior Complete Response Letter.
See our latest analysis for Outlook Therapeutics.
Investors appear to be reacting to the BLA resubmission and upcoming FDA decision. The latest share price is US$1.10, with a 30 day share price return of 353.61%. However, the 1 year total...